Over the past 30 years, progress in early detection and treatment of cancer has helped reduce the overall death rate by more than 30%. Pancreatic cancer, however, has remained difficult to treat. Only 1 in 9 people survive five years after diagnosis, in part because this cancer is protected by biological factors that help it resist treatment. In hopes of turning the tide, UCLA researchers have developed a technology that delivers a combination therapy to pancreatic tumors using nanoscale particles loaded with irinotecan, a chemotherapy drug approved as part of a drug regimen for pancreatic cancer, and 3M-052, an investigational drug that can boost immune activity and help overcome tumors’ resistance.
Login Or Register To Read Full Story